JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

NLR as prognostic biomarker for metastatic renal cell carcinoma patients treated with cytoreductive nephrectomy

  • 0Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Biomarkers in Medicine +

|

February 26, 2025

|

February 26, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Elevated preoperative Neutrophil-to-lymphocyte ratio (NLR) is linked to worse survival in metastatic renal cell carcinoma (mRCC) patients after cytoreductive nephrectomy (CN). This finding can aid clinical decisions for mRCC treatment.

Area Of Science

  • Oncology
  • Nephrology
  • Biomarkers

Background

  • Metastatic renal cell carcinoma (mRCC) is a complex malignancy.
  • Cytoreductive nephrectomy (CN) is a treatment option for select mRCC patients.
  • Identifying prognostic markers is crucial for optimizing mRCC management.

Purpose Of The Study

  • To evaluate the prognostic significance of preoperative Neutrophil-to-lymphocyte ratio (NLR) in mRCC patients undergoing CN.
  • To determine if NLR can predict survival outcomes in this patient cohort.

Main Methods

  • Retrospective analysis of clinicopathological data from mRCC patients (2008-2018).
  • Stratification of patients into low (≤2.7) and high (>2.7) NLR groups based on optimal cutoff.
  • Survival analysis using Kaplan-Meier curves, log-rank tests, and Cox regression models.

Main Results

  • High NLR group showed significantly shorter progression-free survival (PFS) and overall survival (OS) compared to the low NLR group.
  • Median PFS: 8.3 months (high NLR) vs. 17.9 months (low NLR), p=0.003.
  • Median OS: 21.6 months (high NLR) vs. 45.1 months (low NLR), p=0.009.
  • Multivariate analysis confirmed NLR as an independent prognostic factor for PFS and OS.

Conclusions

  • Preoperative elevated NLR is significantly associated with poorer survival in mRCC patients post-CN.
  • NLR serves as a valuable independent prognostic biomarker for mRCC patients undergoing CN.
  • This marker can potentially assist in clinical decision-making for mRCC management.

Keywords: